Clinical Trials Browser

Phase 2/3 × Pancreatic Neoplasms × nimotuzumab × Clear all

NCT06409429 2024-05-10

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT00561990 2015-10-15

Nimotuzumab in Adults With Pancreatic Cancer

Phase 2/3 Completed

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms